15.12.2022 12:17:57 CET | Monsenso |
Selskabsmeddelelse
Monsenso har sammen med et konsortium af europæiske partnere modtaget tildelingsbesked fra en fond om et nyt projekt, som skal udvikle og teste nye, personlige, digitale interventionsprogrammer leveret via Monsenso’s platform for at forebygge mentale lidelser.
Selskabsmeddelelse nr. 16-2022
Monsenso (Nasdaq First North Growth Market Denmark : Ticker MONSO) er forpligtet til at offentliggøre denne information i henhold til EU Markedsmisbrugsforordning.
København, den 15. dec. 2022
Globale trends såsom krig, økonomisk krise, klimaændring, migration, pandemi og aldrende befolkning lægger pres på samfundet i Europa. For at imødekomme dette pres i en foranderlig verden, er der brug for skalerbare interventionsprogrammer som kan hjælpe til at forebygge mentale lidelser.
Med tildelingsbeskeden vil Monsenso starte udarbejdelse af en investeringsaftale med et konsortium af ledende forskere indenfor klinisk psykologi, internetbaseret terapi, kunstig intelligens samt leverandører af psykiatriske ydelser på tværs af Europa. Formålet med projektet er at udvikle og lave kliniske forsøg med et AI-baseret personligt selvhjælpsprogram baseret på Monsensos platform som forebyggende indsats for personer med forhøjet risiko for mentale lidelser. Det femårige projekt forventes at starte i Q2-2023 og bidrage med kr 5,7 mio til Monsenso.
– Dette er det andet projekt omkring AI-baseret personlig terapi, som vi planlægger at starte i det kommende år. Det kommer ovenpå afslutningen af et andet europæisk projekt, hvor resultater har vist signifikant effekt af at levere digital kognitiv adfærdsterapi for at forebygge mentale lidelser. Vi videreudvikler vores platform for at levere personlige, AI-drevne, digitale programmer for personer med forhøjet risikoprofil, så de kan få let og rettidig adgang til evidensbaseret støtte, siger direktør Thomas Lethenborg, Monsenso.
Yderligere beskrivelse af projektet inklusive information om øvrige konsortiemedlemmer, fundingprogrammet og berørte lande vil blive kommunikeret efter underskrift af investeringsaftale, hvilket forventes at være på plads i Q1 2023.
Finansielle forventninger
Projektet ændrer ikke Monsensos finansielle forventninger til 2022, men forventes at bidrage til væksten i 2023 og fremefter.
Yderligere oplysninger:
Monsenso:
CEOThomas LethenborgTlf. +45 21 29 88 27E-mail: lethenborg@monsenso.com
Chairman of the boardPeter Mørch EriksenTlf. +45 51 99 66 00E-mail: petermorcheriksen@outlook.com
Certified Adviser:
Norden CEF A/SJohn NordenTlf. +45 20 72 02 00E-mail: jn@nordencef.dk
Om Monsenso
Monsenso er en innovativ virksomhed, som tilbyder en digital sundhedsløsning til brug for decentaliserede forsøg, patientmonitorering og behandlingsunderstøttelse. Vores mission er at bidrage til bedre sundhed til flere personer og lavere omkostninger ved at understøtte behandling digitalt og bedre udnytte patienters egne data. Vores løsning bidrager til optimering af behandlingen og giver et detaljeret overblik over patienters sundhed via indsamling af data om deres tilstand, adhærens og adfærd. Løsningen forbinder patienter, omsorgspersoner og behandlere for at muliggøre en personligt tilpasset behandling, distancebehandling samt tidlig intervention. Vi samarbejder med sundhedsvæsenet, medicinalindustrien og forskningsinstitutioner verden over i vores forsøg på at levere løsninger som passer ind i patienters og sundhedsprofessionelles hverdag. Få mere at vide på www.monsenso.com
Vedhæftninger
Download selskabsmeddelelse.pdf
Patient with smartphone.jpg
Clinician with clinical web portal.jpg
15.12.2022 12:17:57 CET | Monsenso |
Company Announcement
Together with a European consortium of partners, Monsenso has received a grant letter on a new community-based intervention project that includes development and trial of a digital health intervention delivered on Monsenso’s platform to prevent mental illness among vulnerable groups.
Company announcement no. 16-2022
Monsenso (publ.) (Nasdaq First North Growth Market Denmark: Ticker MONSO) is obligated to publish the information in compliance with the EU Market Abuse Regulation.
Copenhagen, 2022.12.15
Global trends such as war, economic crisis, climate changes, migration, pandemics and ageing population place increasing stress and pressure on European societies. To be able to adapt to fast-changing situations, scalable intervention programmes targeted at building resilience and enhancing self-help competency to prevent mental illness are needed.
Upon receiving this grant letter, Monsenso is now entering into grant agreement negotiations with a consortium of leading researchers in clinical psychology, internet-based therapy, AI and community mental health providers across Europe. The aim of the project is to develop and trial an AI-enabled personalised self-care program based on Monsenso’s platform to help prevent mental illness for high-risk groups. The five-year project is anticipated to start in Q2-2023 and is expected to contribute with DKK 5.7 mio to Monsenso.
– This is the second AI-enabled personalised therapy project that we plan to start in the coming year, and it comes after finalising another European research project this year, where results showed significant effect of delivering digital cognitive behavioral therapy for prevention of mental illness. We will build on the evidence and experience of previous projects and further develop our platform to provide personalised, AI-driven digital programs for people at risk of developing mental illness, so that they can get easy and timely access to evidence-based support, says Thomas Lethenborg, CEO of Monsenso.
Further information on the project including consortium members, funding program and population groups targeted will be communicated upon signature of a grant agreement, which is expected i Q1 of 2023.
Financial expectations
The project does not impact Monsenso’s financial expectations for 2022, but it is expected to contribute to the growth in 2023 and beyond.
Further information:
Monsenso:
CEOThomas LethenborgTel. +45 21 29 88 27E-mail: lethenborg@monsenso.com
Chairman of the boardPeter Mørch EriksenTel. +45 51 99 66 00E-mail: petermorcheriksen@outlook.com
Certified Adviser:
Norden CEF A/SJohn NordenTel. +45 20 72 02 00E-mail: jn@nordencef.dk
About Monsenso
Monsenso is an innovative technology company offering a digital health solution used for decentralised trials, remote patient monitoring and treatment support. Our mission is to contribute to improved health for more people at lower costs by supporting treatment digitally and leveraging patient-reported outcomes data. Our solution helps optimise the treatment and gives a detailed overview of an individual’s health through the collection of outcome, adherence and behavioural data. It connects individuals, carers and health care providers to enable personalised treatment, remote care and early intervention. We collaborate with health and social care, pharmaceuticals and leading researcher worldwide in our endevaours to deliver solutions that fit into the life of patients and health care professionals. To learn more visit www.monsenso.com
Attachments
Download announcement as PDF.pdf
Patient with smartphone.jpg
Clinician with clinical web portal.jpg
